KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Total Non-Current Liabilities (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Total Non-Current Liabilities data on record, last reported at $5.7 billion in Q2 2025.

  • For Q2 2025, Total Non-Current Liabilities changed N/A year-over-year to $5.7 billion; the TTM value through Jun 2025 reached $5.7 billion, changed N/A, while the annual FY2024 figure was $5.1 billion, 19.59% up from the prior year.
  • Total Non-Current Liabilities reached $5.7 billion in Q2 2025 per VRTX's latest filing, up from $5.1 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $5.7 billion in Q2 2025 and bottomed at $2.8 billion in Q2 2021.
  • Average Total Non-Current Liabilities over 5 years is $3.8 billion, with a median of $3.6 billion recorded in 2022.
  • Peak YoY movement for Total Non-Current Liabilities: increased 5.84% in 2021, then grew 23.99% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $3.1 billion in 2021, then increased by 12.92% to $3.6 billion in 2022, then rose by 20.26% to $4.3 billion in 2023, then rose by 19.59% to $5.1 billion in 2024, then grew by 10.9% to $5.7 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $5.7 billion in Q2 2025, $5.1 billion in Q4 2024, and $4.5 billion in Q1 2024.